Prelude Therapeutics (NASDAQ:PRLD) Earns Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Prelude Therapeutics (NASDAQ:PRLD) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Separately, Barclays cut Prelude Therapeutics from an equal weight rating to an underweight rating and set a $3.00 price target for the company. in a research report on Thursday, June 20th.

Prelude Therapeutics Price Performance

Prelude Therapeutics stock opened at $2.77 on Tuesday. The stock has a market capitalization of $152.41 million, a price-to-earnings ratio of -1.47 and a beta of 1.52. Prelude Therapeutics has a 1-year low of $1.66 and a 1-year high of $6.80. The business has a fifty day moving average price of $5.22 and a 200-day moving average price of $4.53.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.46) EPS for the quarter, hitting analysts’ consensus estimates of ($0.46). On average, equities research analysts anticipate that Prelude Therapeutics will post -1.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prelude Therapeutics

A number of institutional investors have recently modified their holdings of PRLD. Acadian Asset Management LLC raised its stake in shares of Prelude Therapeutics by 42.7% during the 1st quarter. Acadian Asset Management LLC now owns 22,110 shares of the company’s stock valued at $104,000 after buying an additional 6,615 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Prelude Therapeutics by 103.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after buying an additional 14,769 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in shares of Prelude Therapeutics during the 1st quarter valued at about $119,000. Pale Fire Capital SE raised its stake in shares of Prelude Therapeutics by 106.6% during the 4th quarter. Pale Fire Capital SE now owns 63,581 shares of the company’s stock valued at $271,000 after buying an additional 32,800 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Prelude Therapeutics by 2.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock valued at $1,990,000 after buying an additional 14,226 shares during the last quarter. Hedge funds and other institutional investors own 79.72% of the company’s stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.